Validation of the Particle-Based Multi-Analyte Technology for Detection of Anti-PhosphatidylSerine/Prothrombin Antibodies.
anti-phosphatidylserine/prothrombin antibodies
antiphospholipid antibodies
antiphospholipid syndrome
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
17 Dec 2020
17 Dec 2020
Historique:
received:
10
11
2020
revised:
11
12
2020
accepted:
14
12
2020
entrez:
22
12
2020
pubmed:
23
12
2020
medline:
23
12
2020
Statut:
epublish
Résumé
Among "extra-criteria" antiphospholipid antibodies (aPL), anti-phosphatidylserine/prothrombin (aPS/PT) antibodies, are considered a part of risk assessment strategies when investigating patients suspected of having antiphospholipid syndrome (APS). aPL detection is currently performed by solid-phase assays to identify anti-cardiolipin (aCL), anti-β2glycoprotein I (aβ2GPI) and aPS/PT antibodies, but new techniques are emerging. Among these, particle-based multi-analyte technology (PMAT), which allows the full automation and simultaneous digital detection of autoantibodies and proteins, including IgG, IgA and IgM isotypes of aCL, aβ2GPI and aPS/PT. The aim of this study was to investigate the agreement of aPS/PT testing between enzyme-linked immunosorbent assay (ELISA) and the PMAT platform. A total of 94 patients were enrolled in the study, including 71 patients with confirmed APS and 23 "aPL carriers". aPS/PT IgG showed a moderate binomial agreement between ELISA and PMAT (k = 0.57, 95% CI 0.45-0.75), and aPS/PT IgM showed a moderate agreement (k = 0.60, 95% CI 0.45-0.75). Moreover, when considering the continuous agreement, both aPS/PT IgG and IgM showed a statistically significant correlation between ELISA and PMAT (Spearman's correlation = 0.69,
Identifiants
pubmed: 33348782
pii: biomedicines8120622
doi: 10.3390/biomedicines8120622
pmc: PMC7766094
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Thromb Res. 2007;120(1):127-33
pubmed: 17020782
Thromb Res. 2019 Mar;175:32-36
pubmed: 30685523
Rheumatology (Oxford). 2013 Aug;52(8):1397-403
pubmed: 23315788
PLoS Negl Trop Dis. 2018 Mar 29;12(3):e0006361
pubmed: 29596412
Rheumatology (Oxford). 2013 Aug;52(8):1358-67
pubmed: 23502076
Clin Chem Lab Med. 2009;47(1):102-8
pubmed: 19072028
Thromb Res. 2014 Mar;133(3):451-4
pubmed: 24342537
Clin Exp Med. 2017 Aug;17(3):257-267
pubmed: 27334977
Clin Rheumatol. 2007 Oct;26(10):1663-70
pubmed: 17332980
Nat Rev Rheumatol. 2017 Sep;13(9):548-560
pubmed: 28769114
Front Immunol. 2019 Mar 05;10:376
pubmed: 30891041
Am J Clin Pathol. 2016 Jun;145(6):796-805
pubmed: 27267373
Rheumatology (Oxford). 2015 Nov;54(11):2042-50
pubmed: 26152548
Arthritis Res Ther. 2020 Feb 21;22(1):33
pubmed: 32085759
Clin Chem Lab Med. 2018 Sep 25;56(10):1734-1742
pubmed: 29626412
Semin Thromb Hemost. 2018 Jul;44(5):453-457
pubmed: 28470650
J Thromb Haemost. 2006 Feb;4(2):295-306
pubmed: 16420554
J Immunol Methods. 2019 Nov;474:112661
pubmed: 31442464
Blood. 2003 Mar 1;101(5):1827-32
pubmed: 12393574
Lupus. 2020 Apr;29(5):463-473
pubmed: 32106789
Ann Rheum Dis. 2003 Dec;62(12):1127
pubmed: 14644846
Rheumatology (Oxford). 2013 Mar;52(3):501-9
pubmed: 23159889
Thromb Haemost. 1995 Oct;74(4):1185-90
pubmed: 8560433
J Thromb Haemost. 2009 Oct;7(10):1737-40
pubmed: 19624461
Rheumatology (Oxford). 2019 Sep 1;58(9):1655-1661
pubmed: 30938432
J Thromb Haemost. 2016 Aug;14(8):1530-48
pubmed: 27279342
Autoimmun Rev. 2020 Oct;19(10):102641
pubmed: 32801044
Thromb Haemost. 2014 Feb;111(2):354-64
pubmed: 24172938
Scand J Clin Lab Invest Suppl. 2010;242:27-33
pubmed: 20515273
Clin Chem Lab Med. 2020 Apr 10;58(9):1499-1507
pubmed: 32286240
Blood. 2003 Oct 15;102(8):2717-23
pubmed: 12816875
Int J Lab Hematol. 2014 Jun;36(3):352-63
pubmed: 24750682